Mer­ck ad­mits cy­ber­at­tack is hav­ing an im­pact on re­search, man­u­fac­tur­ing — we're just not sure how big

Mer­ck is still grap­pling with just how much dam­age they’ve in­curred as a col­lat­er­al vic­tim of the Not­Petya at­tack one month ago. And as a di­rect con­se­quence, they’re cut­ting their prof­it out­look and sig­nal­ing de­lays with some prod­uct sup­ply or­ders.

The phar­ma gi­ant dis­closed the news this morn­ing in their earn­ings re­port, with CFO Rob Davis telling an­a­lysts the com­pa­ny is still “as­sess­ing the full im­pact.”  But it has clear­ly had an im­pact on the num­bers. “The guid­ance would have been high­er with­out the cy­ber­at­tack,” Davis added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER